Effect of biologics on cardiovascular comorbidities of psoriasis / 中华皮肤科杂志

ABSTRACT

Psoriasis is prone to be accompanied by cardiovascular diseases. Psoriasis and atherosclerosis have similar pathogenesis, involving the activation of innate immunity and autoreactive T cells. In recent years, more and more biological agents have been applied to systemic treatment of psoriasis, including tumor necrosis factor-α, interleukin-12/23 inhibitors and interleukin-17A inhibitors. The efficacy and safety of different biological agents, as well as their impact on cardiovascular diseases, have also attracted the attention of dermatologists. This review summarizes the common immunological pathogenesis of psoriasis and atherosclerosis, as well as the effects of different biological agents on cardiovascular diseases and related metabolic changes.